Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective Study
Authors' conclusion
Significant hs-TnT elevations occur more often than previously reported, are often asymptomatic, and do not always lead to myocarditis diagnosis.
Study context
- Population
- Cancer patients receiving ICI therapymean follow-up 1.60 ± 0.91 years
- Participants
- 164 patients
- Outcome
- Kinetics of hs-TnT and association of elevated hs-TnT (≥14 ng/L) and significant hs-TnT rise (100% rise from baseline, absolute value ≥28 ng/L) with ICI-myocarditis
Methodological detailsobservational, single-centre
- Observational
- Single-centre
Main finding
As reported in the abstract
- Significant high-sensitivity troponin T (hs-TnT) elevations
- 26 (16%)
- ICI-myocarditis
- 8 (5%)
- Significant hs-TnT elevation where ICI-myocarditis could not be diagnosed with certainty
- 18 of 26 (69%)
- Significant hs-TnT elevation with no other signs or symptoms of cardiac damage
- 10 of 26 (38%)
- All myocarditis cases preceded by significantly higher hs-TnT elevations than asymptomatic patients
- 8
Observational data: associations, not effects.
Further findings
- Cardiac mortality
- 4%
Original publication
Elevations of Cardiac Troponin in Patients Receiving Immune Checkpoint Inhibitors: Data From a Prospective Study. JACC Adv. Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →